Posts

November 13th, 2010

Sweet Home Chicago: An AHA Meal Planner

Several Cardiology Fellows who are attending this week’s AHA  meeting are blogging together on CardioExchange. The Fellows include Susan Cheng, Madhavi Reddy, John Ryan, and Amit Shah. Check back often to learn about the biggest buzz in Chicago this week — whether it’s a poster, a presentation, or the word in the hallways. Here’s our first post.

Chicago has been my home now for a year and a half since I started fellowship. As many of you know, it has a lot to offer, including architecture, downtown beaches, and Oprah Winfrey. Most of all, though, here in the Windy City, we are very well known for our fine food.

I have compiled a list of my favorite restaurants, most of which are in a reasonable price range and should have availability over the next few days. Be warned though, once you are eating in “the Loop” you are going to pay at least $30-$40 per person (there is no real way of getting around that). Let me know which ones you like, which ones you would not recommend, and when you get there, don’t forget to tell them that John sent you!

Deep dish pizza:
Lou Malnati’s

Chinese:
Ed’s Potsticker House
Happy Chef  Dim Sum House

French:
Chez Joel
Avec
Blackbird
Cafe Matou

Mexican:
Frontero
Maiz (cheap, good margaritas)
Fonda del Mar (seafood)

Steak:
Chicago Chop House
Gibsons

Italian:
Area ->  Heart of Italy (23rd and Oakley)
A Tovola (pricey) (next to UIC)

Sushi:
Marai
Japonais

Ethiopian:
Ethiopian Diamond

Irish:
Duke of Perth

Indian:
India House
Little India

Udupi Palace (South Indian), West Devon Ave.

Vietnamese
Argyle Street (Pho 777, Tank Noodles)

Korean:
Cho Son Ok (N. Lincoln and Montrose)

Thai:
TAC Quick (Sheridan and Irving Park, near Wrigley field, ask for authentic menu)
Spoon Thai
Arun’s (expensive but good, 4 stars)

November 13th, 2010

Study Explores Role of Familial AF in Risk of Developing New AF

Although it is well known that there is a heritable component to atrial fibrillation (AF), the precise clinical significance of familial AF has been unclear. Steven Lubitz and colleagues analyzed data from the Framingham Heart Study to assess the incremental predictive value of familial AF in a risk model for new-onset AF.

In a presentation at the American Heart Association meeting in Chicago and a simultaneous online publication in the Journal of the American Medical Association, the authors report that familial AF was an independent risk factor and was associated with a 40% increase in the risk of developing AF. The addition of familial AF slightly increased the predictive accuracy of the risk model. Premature familial AF was the most powerful AF feature examined.

“Future efforts should attempt to discern the factors that mediate the association between familial AF and AF risk, further explore the relationships between premature familial AF and risk prediction, and determine whether incorporating genetic variants into an AF prediction model enhances its performance,” the authors concluded in their JAMA paper.

November 12th, 2010

Time Out!

This week, JAMA published a commentary that Harlan Krumholz and I wrote about the growing use of ad hoc PCI and its implications for decision making about coronary revascularization. To cut to the chase, we believe that ad hoc PCI — the performance of a diagnostic cath and PCI in the same setting — makes it challenging to incorporate findings from landmark studies like the COURAGE and SYNTAX trials into routine clinical practice. As a solution, we suggest that in stable patients, interventionalists consider “pausing” for a few days between the diagnostic cath and the PCI. Bill Boden — the lead investigator of the COURAGE trial — is currently exploring the feasibility of implementing such a waiting period in a collaborative effort with payers in upstate New York. Existing payment systems often discourage two separate settings for diagnostic cath and PCI because doing them at the same time is deemed more efficient. However, we are concerned that we may be performing PCI on patients who would have done just as well with optimal medical therapy or whose coronary anatomy would have been better suited to coronary bypass surgery.

But I think the biggest hurdle that Bill and others may face in such endeavors is the public’s distorted view of PCI. A recent study shows that patients continue to have outsized expectations about the benefits of PCI that are simply unjustified by the available evidence. As an interventionalist, I’ve found that patients (and referring providers) frequently arrive at the cath lab with the belief that if a blockage is found, it should be “fixed” right away. This places undue pressure on everyone to make immediate decisions that may not be in the best interest of the patient.

So, do others feel this type of pressure as well? Is a “pause” something that physicians, insurers, and patients would agree to implement in your practice?

November 11th, 2010

Heart Failure: A Scary Name That Doesn’t Make Sense

Well-known science journalist Mary Knudson is the author of HeartSense, a blog about heart failure, from which the following post is taken. In this post, she questions the aptness of the designation “heart failure.”

For the last week, I have been mulling over the term heart failure, questioning how the collective conditions that bear this label ever got such a name, and looking into the very murky area of heart failure death statistics.  Many, many of us who were shocked to get the frightening diagnosis heart failure do not have hearts that have failed.  We got treated, some more quickly than others, and went right on with our lives.  Others are not so lucky and die of heart failure, sometimes suddenly and sometimes after years.  Trying to discuss heart failure becomes very difficult because it is not a disease, it is a syndrome brought on by many different underlying causes, including coronary artery disease, disease of the heart muscle, high blood pressure, valve malfunction, poor artery connection, alcoholism or drug abuse, and certain chemotherapies, to name just a few.  And heart failure affects the heart in different ways.

Heart failure covers conditions ranging from no symptoms to severe shortness of breath resulting from fluid collecting in the lungs; swelling of the abdomen, ankles and feet; and fatigue, even at rest. See the American College of Cardiology/American Heart Association Stages of Heart Failure and New York Heart Association Classification of the stages of heart failure here.

Somehow, so much is encompassed under the same heart failure umbrella that discussing the syndrome is confusing for physicians and patients.  “Skilled clinicians have difficulty with this, and most fumble around,” James B. Young,  Professor of Medicine and Executive Dean, Cleveland Clinic Lerner College of Medicine, told me in an e-mail. So to write about what medicine calls heart failure, what’s wrong with the name, and what, if anything, to do about it, is challenging.

Then, yesterday, something happened that clarified the picture for me.  I knew when I got a pit bull from a rescue organization a year ago that he had a kidney problem, and I agreed to take him because he had a terrible earlier life that included months spent in a cage that nearly drove him insane.  I wanted to give him a loving home for whatever time he had, a year or two.  He arrived with skin hanging over his skeleton, but he had a great appetite and put on weight, filling out very normally, enjoying his walks, and loving to play catch-me-if-you-can with a nylon bone or an old house shoe every time one of us returned home.

Then in the last week, things changed.  He started throwing up, and for the last four days he could not keep anything down.  He was noticeably losing weight.  His very thick neck thinned in a matter of days, and his spinal column began to protrude.  On a walk, he would only go one block before turning to go home.  He quit playing catch-me.  He lay constantly on his bed, or at night, my bed.  Monday we took him to the vet, and yesterday morning we got his blood test results.  His blood urea nitrogen (BUN) was 237, the highest my vet had ever seen.  A normal BUN level in a dog is 6 to 31.  A high BUN level indicates that toxins are not being removed by the kidneys.  My dog was in kidney failure, my vet told me.  That was the first time I was told he was in kidney failure.  And those words made a lot of sense.  Teddy was not in kidney failure for the last year, only for the last few days.  His kidneys indeed had failed.  If he were a person, he would have had to either go on dialysis or get a kidney transplant in order to live.  Teddy was miserable, had lost weight quickly, and had grown a tumor which I would have wanted removed were it not for the kidney failure.  The vet said that the anesthesia itself could be so toxic to the kidneys that it might kill Teddy.  And so at noon, with tears and heavy heart, to end his suffering, we had him put to sleep.

Yesterday afternoon, in a house far too quiet, I tried to return to writing.  And then I got to thinking.  Kidney failure.  Heart failure. The two terms sound alike but are used by doctors very differently.  But why?  In kidney failure, the kidneys don’t work anymore.  It’s so obvious you hardly need a blood test to prove it.  As with heart failure, many different things may have caused it, and the kidney failure may have come on gradually or acutely, but kidney failure is kidney failure.  It means what it says.  Contrast that with heart failure, where most of the time when the diagnosis is made, the heart is still working.  It has not failed, although something about the heart is not normal and may have begun to cause symptoms.  But if the heart had failed, as the kidneys have in kidney failure, the patient would need a machine to circulate blood throughout his system, or an implanted device that takes over at least some heart function, or a heart transplant to live.

Heart failure is an appropriate term for the condition now described as end-stage heart failure, in which patients have, at most, months to live unless mechanical aid (e.g., a ventricular assist device) takes over part or all heart function or the patient gets a heart transplant.  But I submit that this is the only true heart failure. Just drop the first word, because end-stage heart failure is redundant.

Heart failure is not an appropriate diagnosis for people who have no symptoms or whose symptoms can be improved or even disappear with treatment.

Why does it matter what conditions are called heart failure?  Why does it matter how many people hear a diagnosis of heart failure?  Shouldn’t I just leave the naming of medical conditions and diseases to doctors and mind my own business?  What’s in a name?  Here’s why it matters:  As I consider the effect the words heart failure can have on a patient, I am reminded of an event that happened to me while I was in college.

Occasionally someone can say something to you that is so scary it seems it might scare you to death.  Near final exam time, I quite suddenly came down with a paralyzing illness, transverse myelitis, and had the misfortune to be hospitalized where doctors had never seen this viral illness, did not recognize it, and decided to operate, looking for an obstruction they did not find. While inside me for “a look-see”, the general surgeon cut into inflamed tissue to take out my healthy appendix.  Already very sick and rapidly becoming paralyzed, I nearly hemorrhaged to death from the surgery and was placed on the hospital’s critical list of patients who may die.

While I knew how terrible I felt, neither doctors nor family had let me know how very sick I was.  The sight of my 8-year-old, blond, cherub-faced nephew cheered me. This was his first visit, and I could tell he was excited about something and wanted to share it with me.  How sweet.  He came right up to my bedside.

“Hey, Aunt Mary,” he gushed, “Do you know you’re on the CRITICAL LIST?”

AAAAAAhhhhhh!  Terror hijacked my entire body.

No, Gary, nobody had told me.  Who let this kid in the room?  There’s a reason that children shouldn’t be allowed in hospitals.  I couldn’t speak.  A numbness began in my feet and crept up my legs.

This story, still so vividly recalled, comes to mind as I write because, like the words critical list, the term heart failure is very frightening, and much of the time, unnecessarily so.  Every day, thousands of people are frightened to learn they have heart failure.  I was.  Never having had any known heart problem, I sat in shock when a cardiologist told me in 2003 that I had HEART FAILURE.  When a doctor tells you that, it’s like being told you have end-stage cancer. You know nothing about heart failure, probably have never heard of it, and it sounds quite fatal.  I went home and made out a will, then spent several months educating myself about heart failure and going from doctor to doctor, searching for the right treatment, afraid that I could drop dead at any moment.

It’s one thing for an 8-year-old kid to scare a sick patient, quite another for a grown-up doctor to do it.   I realize that there are many times when a doctor has to give a frightening diagnosis, and I appreciate that this is emotionally hard for many caring doctors.  But, Doctors, do you ever wince when you tell a patient she has heart failure when you believe that proper medications may make a big change in her symptoms?  I ask doctors to be more aware that a diagnosis is a two-way communication:  It is words the physician says, and it is words the patient hears. One is just as important as the other.  Your diagnosis is not complete, doctors, until the patient has heard it.

I was not able to find out who originated the term heart failure as a diagnosis.  Renowned cardiologist-historian Arnold M. Katz  told me, “It will be hard to find out who (first) used the term heart failure, as most of the early texts were written in Latin, a language I do not speak.”  But the name got into the medical literature long ago before modern therapies were available.

I wish the medical community would find a new term. How about heart flux or heart fatigue or heart stress syndrome for this condition that now wears one inappropriate label disturbing and confusing to patients and their close circles? How much easier and more exact for your patient to hear, “Your heart is in a state of flux (or fatigue, or stress), and I have some medications to give you that have a good chance of helping a lot,” instead of “You have heart failure.”

Until then, I hope that when pronouncing the scary words heart failure to a new patient, doctors will take the time to explain that, much of the time, it’s not what it sounds like.

November 10th, 2010

Alzheimer’s Disease and Cholesterol: A Tricky Relationship

A recent study in Neurology found that cholesterol levels in mid-life were not linked to the development of Alzheimer’s disease in older age. In fact, the study by Michelle Mielke and colleagues found that large drops in cholesterol levels in old age were a harbinger of Alzheimer’s. CardioExchange asked Cynthia Carlsson, Assistant Professor and Alzheimer’s researcher at the University of Wisconsin School of Medicine and Public Health, to provide an expert perspective on this counterintuitive finding.

There has been a lot of controversy as to what role cholesterol plays in the development of dementia. To date, studies suggest that elevated midlife cholesterol increases the risk of Alzheimer’s disease. This idea is also supported by animal studies that show increased cholesterol triggers the development of the hallmark amyloid plaques in the brains of animals. In addition to Dr. Mielke’s study, other investigators have shown in longitudinal analyses that blood cholesterol levels tend to be higher in midlife and then drop later in life prior to the onset of dementia.

Some believe this reflects the subclinical disease process leading to either dietary changes or other inflammatory changes that alter the blood cholesterol levels. Because serum cholesterol is a negative, acute-phase reactant, with an increased inflammatory state (such as during acute or chronic illness) serum cholesterol levels decline. Alzheimer’s disease is associated with inflammatory changes; thus, it could theoretically trigger a decline in serum cholesterol.

Therefore, I am not too surprised that Dr. Mielke found that those individuals with the greatest cholesterol decline had the highest risk of Alzheimer’s disease: These results most likely reflect that the person is progressing to a disease state, rather than the low-cholesterol levels triggering the dementia.

November 9th, 2010

Statement from AHA, ACC, and ACG Reaffirms Use of PPIs with Antiplatelet Therapy

Despite recent warnings by the FDA, an expert consensus document released jointly by the AHA, the ACC, and the American College of Gastroenterology states that it is acceptable to use proton pump inhibitors (PPIs) with thienopyridines like clopidogrel in patients at high risk for upper GI bleeds. The statement does not recommend routine use of PPIs in patients on antiplatelet therapy.

Although pharmacokinetic and pharmacodynamic studies suggest that the antiplatelet effects of clopidogrel can be reduced  by a PPI, “it is not established that changes in these surrogate endpoints translate into clinically meaningful differences,” according to the statement. However, the statement acknowledges that “a clinically important interaction cannot be excluded, particularly in certain subgroups, such as poor metabolizers of clopidogrel.”

Finally, the clinical role for pharmacogenomic or platelet function testing “has not yet been established.”

“The flurry of conflicting data published following the 2008 Expert Consensus Document left many practitioners confused,” said Neena Abraham, the chair of the writing committee, in a press release. “However, much of the published data used results of platelet function tests as surrogate markers of cardiovascular risk. The differences in drug levels and in platelet function studies caused concern about an adverse drug interaction, but the clinical significance of these laboratory test results has not been substantiated when held to the higher scientific standard of large patient studies with clinically relevant endpoints, such as heart attacks or strokes.”

November 9th, 2010

Intensive Statin Therapy Examined in Meta-Analysis and SEARCH Trial

A new meta-analysis and a large clinical trial shed new light on the additive effects of intensive statin therapy over standard therapy. The meta-analysis from the Cholesterol Treatment Trialists’ Collaboration and the results from SEARCH (Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine) are published online in the Lancet.

The meta-analysis examined individual patient data from nearly 40,000 patients enrolled in five  trials comparing intensive versus standard statin therapy and nearly 130,000 patients enrolled in 21 trials of statin therapy versus controls. Major vascular events were reduced by 15% in the intensive versus standard therapy arm. When all trials were combined, the authors observed a 20% reduction in deaths due to coronary heart disease associated with each 1.0 mmol/L reduction in LDL. The authors report that they found no significant evidence “that further lowering of LDL cholesterol … produced any adverse effects”, thereby “suggesting that reduction of LDL cholesterol by 2-3 mmol/L would reduce risk by about 40-50%.”

The SEARCH trial, which was originally presented in 2008 at the AHA, compared the effects of 80 mg versus 20 mg simvastatin in 12,000 patients with a history of MI. The SEARCH Collaborative Group reported a nonsignificant 6% reduction in major vascular events from 25.7% in the 20-mg arm to 24.5% in the 80-mg arm. Myopathy occurred in 0.03% in the 20-mg group compared with 0.9% in the 80-mg group. The authors conclude that “for patients deemed to be at sufficient risk of major vascular events, a more appropriate strategy (by contrast with current guidance) could be to consider regimens involving newer, more potent, statins… or the combination of standard doses of generic statins… with other agents that can lower LDL cholesterol substantially without producing such increases in the risk of myopathy.”

In an accompanying editorial, Bernard Cheung and Karen Lam write: “People with substantial cardiovascular risk should have intensive lipid-lowering therapy. A low baseline LDL concentration is not a reason to withhold statin therapy if the patient is at a definite risk of cardiovascular events (eg, secondary prevention or diabetes). In this setting, the absolute risk reduction, number needed to treat, and risk–benefit and cost–benefit ratios are favourable. These numbers will be less persuasive for people at low cardiovascular risk, such as young people with no risk factors.”

November 8th, 2010

Non-STEMI Patients Delay Seeking Help Just As Long as STEMI Patients

Non-STEMI patients delayed going to the hospital for as long in 2006 as they did in 2001, according to a report published in the Archives of Internal Medicine. Henry Ting and colleagues analyzed data from 104,622 non-STEMI patients enrolled in the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) registry and found that the median delay time from the onset of symptoms to hospital arrival was 2.6 hours. Nearly 60% of patients took at least 2 hours before arriving at the hospital.

Delay times for STEMI and non-STEMI patients are similar, the authors report. They write: “Because patients cannot differentiate whether symptoms are due to STEMI or non-STEMI, early presentation is desirable in both instances,” adding: “Novel strategies to improve patient responsiveness to seek care are critical and important for both patients with STEMI or non-STEMI.”

November 8th, 2010

AHA 2010 Coverage Headquarters

CardioExchange has been dedicated to bringing you the latest from AHA 2010, and even though the meeting has ended, the buzz has just begun! Check out our coverage below ─ and the great debates these posts have sparked ─ then tell us what you think!

Previews:

News:

Analysis:

  • What Does BASKET PROVE Have to Prove? In the BASKET PROVE trial, drug-eluting stents were just as good as bare-metal stents for treating lesions in large coronary arteries. Interventional Cardiology Co-Moderators David Hillis and Rick Lange discuss the relevant issues.
  • Putting the EMPHASIS on Eplerenone for HF We welcome Paul Armstrong to answer our questions about the EMPHASIS-HF study, in which eplerenone reduced the rate of cardiovascular death and heart-failure hospitalization in patients with functional NHYA class II HF. (Paul’s editorial on the study appears in the NEJM).
  • How Should We DEFINE Anacetrapib’s Success? Philip Barter and Christopher P. Cannon answer our questions about their DEFINE study, in which anacetrapib had a “knock-your-socks-off effect on HDL and a jaw-dropping effect on LDL.”
  • A Clinical Conversation with Harlan Krumholz: CardioExchange and AHA In a Journal Watch Clinical Conversations podcast, Editor Harlan Krumholz discusses CardioExchange and what he thinks of the top research presented at AHA 2010. We also showcase Harlan’s posts at Forbes on remote patient monitoring (including his own Tele-HF study) and on the DEFINE study.

Follow with the Fellows:

  • AHA: A Global View Reflecting on her first day at AHA, Madhavi Reddy writes about the surprising amount of advertising from one manufacturer, a sobering talk about the state of clinical research in the U.S., and an uplifting session that provided practical advice on incorporating global research into clinical practice.
  • Blast off to AHA: A Call for Solutions to the Obesity Epidemic in America Amit Shah’s flight was delayed to AHA because his plane was too heavy for takeoff due to the collective weight of the passengers. Thinking about the obesity problem we have in the U.S., Amit writes, “I was grateful for the conference ahead; only by putting our minds together can we start to understand and address one of the most challenging and weighted issues in America.”
  • Networking at AHA John Ryan shares that if you take advantage of certain sessions and dinners at the AHA, there are great opportunities to network with leaders in cardiology.
  • An Exceptional Late-Breaking Session After confessing that she normally avoids late-breaking sessions “like the plague”, Susan Cheng focuses on one such session with both important science and important lessons about presenting.
  • AHA Science and Technology Hall After working up a sweat on an AHA-endorsed Wii skateboard in the exhibit hall, John Ryan wonders how quickly attendees take what they learn in the sessions and incorporate it into their clinical practice.
  • First-Time Presenter John Ryan recounts the trials and tribulations of giving his first talk at AHA.
  • Is There A Statistician In the Room? Feeling a bit stumped by some of the statistical concepts she encountered at some AHA sessions, Susan Cheng wonders, “Could there be a way to help the average conference attendee make better sense of methods in order to better make sense of the results?”

We’re curious: What trials presented at AHA had the biggest impact on you? Let us know.

November 8th, 2010

Up-Front Clopidogrel Loading Versus Common Sense

From time to time, a sales representative visits my office promoting clopidogrel (Plavix) as a drug that patients who present with unstable angina/non–ST-segment-elevation MI (UA/NSTEMI) should start immediately as an up-front load. That strategy hasn’t been uniformly accepted in my clinician community because of concern about using an irreversible antiplatelet agent to treat patients who might need coronary artery bypass graft (CABG) surgery. Yet, this notion of clopidogrel pretreatment before cardiac catheterization is widely viewed as a given.

Like most busy practitioners, I can be a fast-food consumer of the clinical trial literature. I often rely on experts for summary recommendations, and I can be susceptible to marketing and other influences. So to delve into the clopidogrel issue, I had to stop and take time to review ACC/AHA guidelines and data from clinical trials. When I did that, I discovered that the evidence for treating patients with unknown coronary anatomy with an up-front load of clopidogrel is weak and indirect.

What I Found

No question, clopidogrel is a useful, effective drug. It has enabled the use of stents, particularly drug-eluting stents, and a loading dose of clopidogrel speeds the onset of action. So, up-front loading makes perfect sense for patients scheduled for PCI. But for the larger group of patients with UA/NSTEMI, there’s a substantial downside. In the large CURE trial, 16.5% of patients required CABG. A 5-day “Plavix washout” for so many patients creates severe logistical problems. If you extrapolate to the 1.24 million UA/NSTEMI patients admitted to U.S. hospitals each year, “Plavix washout” would result in more than a million patient-days in hospitals — an enormous expense and inconvenience just to compensate for up-front loading.

What’s the evidence that this costly strategy works? The CURE trial, which is widely referenced, really didn’t test up-front loading. It assessed the effect of adding clopidogrel as a loading and maintenance dose to aspirin over a follow-up period of up to 12 months. Patients were loaded as soon after randomization as possible, but the trial’s protocol did not specify the timing of cardiac catheterization. Patients who underwent PCI experienced a median delay to PCI of 10 days, hardly reflecting current care in the U.S. And clopidogrel treatment came with a cost of excess bleeding, particularly at vascular access sites.

In the CURRENT-OASIS 7 trial, a strategy of double-dose clopidogrel as an up-front load and for 6 days, followed by standard dosing, was compared with standard loading and dosing in acute coronary syndrome patients (ACS) who were referred for an invasive strategy. The primary endpoint did not differ significantly between the two treatment groups. The study did not specifically isolate the issue of up-front loading, but up-front loading and 6-day treatment with a stronger dosing regimen did not show a benefit.

Then there’s the CREDO trial, in which patients undergoing PCI either received a 300-mg clopidogrel preload then 75 mg daily for 12 months or no load at all then 75-mg daily for 28 days. Preloading and long-term clopidogrel showed a significant advantage in reducing a combined endpoint of death, MI, or stroke over a year — but not in a combined endpoint of death, MI, or urgent target-vessel revascularization over 28 days — suggesting that the benefit was due to long-term treatment, not the up-front load. PCI-CURE, a subgroup analysis of CURE that is also widely referenced, showed a favorable effect of clopidogrel in patients undergoing PCI but did not specifically address the timing of drug initiation.

How I Reason

No trial has specifically compared up-front clopidogrel loading with loading that is delayed until after a patient’s coronary anatomy is known. Furthermore, the argument for up-front loading ignores the availability and proven benefits of short-acting, reversible glycoprotein IIb/IIIa-receptor antagonists. Also, faster-acting thienopyridines (prasugrel and, soon, ticagrelor) that can be loaded at the time of cardiac catheterization are available. The most logical strategy would be to determine the coronary anatomy quickly so that the best revascularization treatment can be planned and appropriate adjunctive therapy can be started in a timely fashion. If catheterization is delayed, a glycoprotein IIb/IIIa-receptor antagonist could be used to bridge the gap in high-risk patients. This common-sense approach prevails in my clinician community.

So how did the practice of up-front clopidogrel loading gain such momentum without stronger evidence from clinical trials? For the sales force, there’s an obvious commercial motivation; for others, perhaps some overinterpretation of industry-funded trials. But for us clinicians, the issue may be overtreatment bias: ACS patients remain at risk for unfavorable outcomes, and doctors are motivated to mitigate that risk. If clopidogrel and similar agents weren’t double-edged swords, erring on the side of overtreatment might be justified, but we must remember that our first principle is to do no harm.

What I Conclude

My assessment is that clopidogrel loading before cardiac catheterization of UA/NSTEMI patients has not been directly studied, has no proven benefit, and carries the obvious disadvantage of irreversibly affecting platelet function in patients who may require CABG. Until proven otherwise by direct clinical evidence, this widely promoted assumption should be rejected and common sense should prevail. That’s how I see the issue. What about you?